NCT07091500View on ClinicalTrials.gov

Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2029

Conditions
ObesitySkeletal Muscle
Interventions
BEHAVIORAL

Exercise training

Participants will perform supervised exercise training sessions 3 days per week and unsupervised at-home sessions 2-3 days per week.

DRUG

Semaglutide

semaglutide 2.4 mg subcutaneous per week or max tolerated dose and diet behavior counseling

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT07091500 - Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity | Biotech Hunter | Biotech Hunter